Genome Valley to host Aurigene Pharma facility

Hyderabad Aurigene Pharmaceutical Services Ltd, a contract research, development, and manufacturing services organization and a step-down subsidiary of Dr Reddy’s Laboratories, has decided to establish a state-of-the-art development and manufacturing facility focused on niche areas like therapeutic proteins, antibodies, and viral vectors in Hyderabad.

Satish Reddy, Chairman, Dr Reddy’s Laboratories and Akhil Ravi, Chief Executive Officer, Aurigene Pharmaceuticals Services Limited, met Minister for Industries and Commerce KT Rama Rao to brief him on upcoming facility and growth plans of Aurigene Pharmaceutical Services for Hyderabad. Jayesh Ranjan, Principal Secretary, Industries & Commerce and Shakthi Nagappan, Chief Executive Officer, Telangana Life Sciences were also present during the meeting.

The leadership of Aurigene informed the Minister that the primary objective is to generate employment opportunities through the investment of $40 million (roughly Rs 330 crore). With the current investments, they anticipate creating approximately 200 direct job positions and another 60-70 indirect job opportunities within the next three years of current investment plans. Further, the company envisions significant scaling-up their investments in the future, which would result in a multi-fold increase in employment prospects in very advanced science and manufacturing technologies. Minister KT Rama Rao said: “I am delighted that Aurigene has chosen Genome Valley to establish their State-of-the-art R&D and manufacturing facility. This investment is aligned perfectly with the Telangana government’s vision to enhance ‘Complex manufacturing at scale’ wherein the objective is to make giant leap towards advanced therapeutic modalities.”